Traditionally, breast cancer treatment is a combination of surgery, chemotherapy, endocrine therapy and radiation therapy, but at the end of last century, with the development of medical science, people conducted in-depth research on the causes of malignant tumors, and the mechanism of genetic carcinogenesis slowly became clear. molecular targeted therapy. As a result, tumor therapeutics has entered a new era of molecular biology. Molecular targeted therapy is to design the corresponding therapeutic drugs at the cellular molecular level, targeting the well-defined oncogenic sites, and the drugs will only combine and act specifically with these oncogenic sites after entering the body, leading to the specific death of tumor cells without endangering the normal tissue cells around the tumor. Therefore, molecular targeted therapy is also called “biological missile”. Currently, molecularly targeted therapies for breast cancer include: anti-Her-2 monoclonal antibodies trastuzumab (Herceptin) and patuximab, treatments targeting EGFR family members (lapatinib, gefitinib, erlotinib, cetuximab, nitrozumab, sunitinib, sorafenib, etc.), monoclonal antibodies against VEGF (bevacizumab, etc.), and inhibitors against other signaling pathway inhibitors such as mTOR, ras, MEK, etc.